Academic research teams of selected projects participate in a translational research program that eliminates barriers that prevent promising discoveries from...
ATLANTA, April 03, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biopharmaceutical company focused on...
Next Generation AI-Driven Analytics to Unlock Key Insights from the Ongoing Continuous Blood Glucose Monitoring Clinical Study DataRUTHERFORD, N.J. and...
VANCOUVER, British Columbia, April 03, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB...
- The oversubscribed private financing round, with primary participation from Fidelity Management & Research Company, The Column Group, Soleus Capital,...
NDA Submission On-Target for Mid-2025KANSAS CITY, Kan., April 03, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing...
Three-year data from NeuroPace’s Post-Approval Study of the RNS® System in drug-resistant focal epilepsy to be shared in oral presentationMOUNTAIN...
Temporomandibular joint (TMJ) osteoarthritis is a degenerative, debilitating and progressive disease, the second most common musculoskeletal condition affecting five to...
STAFFORD, Texas, April 03, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused...
On track to announce primary endpoint result from ORIGIN 3 trial this quarter (2Q 2025)U.S. FDA BLA submission for accelerated...
-- Novel, locally administered gene therapy designed to boost cellular production of anti-inflammatory protein IL-1Ra in the knee -- --...
MELBOURNE, Australia and SAN FRANCISCO, April 03, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the...
CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on...
MNV-201 is Minovia’s second generation mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with allogeneic mitochondria Rare...
Press release LIfT BioSciences gains access to half a million allogeneic donors through collaboration with Gift of Life Biologics Access...
Agreement with Hercules Capital significantly increases financial and operational strength, provides up to $500 million in capital with no dilution...
SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology...
Press release LIfT BioSciences gains access to half a million allogeneic donors through collaboration with Gift of Life Biologics Access...
Ad hoc announcement pursuant to Art. 53 LR Vanrafia can be seamlessly added to supportive care in IgAN and used...
To be presented at 11th Annual Immunotherapy of Cancer (ITOC) Conference in Munich, Germany Marlborough, Massachusetts--(Newsfile Corp. - April 3,...